DrugBiological

Sacituzumab tirumotecan clinical trials

Also written SKB264 and MK-2870.

studies test it: 95
open now: 79
in phase 3: 27
first study started: 2020

Keep track of what changes. Save the sacituzumab tirumotecan studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Studies by the year they started

91 studies that test it; most in 2026 (43); 4 more planned to start later

Studies that test sacituzumab tirumotecan, by start year
Year	Studies
2020	1
2022	2
2023	7
2024	13
2025	25
2026	43

By phase

A phase 1/2 study counts in both.

Phase 1: 7
Phase 2: 66
Phase 3: 27
No phase: 1

What it is tested for

Each study’s main condition, where its own words name it.

Carcinoma, Non-Small-Cell Lung: 20
Triple Negative Breast Neoplasms: 11
Breast Neoplasms: 5
Uterine Cervical Neoplasms: 4
Esophageal Squamous Cell Carcinoma: 4
Urinary Bladder Neoplasms: 3
Carcinoma, Ovarian Epithelial: 2
Endometrial Neoplasms: 2
Prostatic Neoplasms: 2
Biliary Tract Neoplasms: 2
Small Cell Lung Carcinoma: 2
Lung Neoplasms: 2

Who runs them

Industry 39 · Other 56

Merck Sharp & Dohme LLC (22) · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (15) · Fudan University (7) · Tianjin Medical University Cancer Institute and Hospital (6) · Klus Pharma Inc. (2) · M.D. Anderson Cancer Center (2) · Latin American Cooperative Oncology Group (2) · Guangdong Association of Clinical Trials (2)

Often tested with

Tested in the same studies.

Pembrolizumab (7) · Toripalimab (5) · Tagitanlimab (5) · Anlotinib (4) · Anti-PD-1/Anti-VEGF-A Bispecific Antibody CR-001 (3) · Paclitaxel (3) · Bevacizumab (2) · Osimertinib (2)

Studies

Open first, then newest update. How each study uses sacituzumab tirumotecan is read from its arms, and is right about nine times in ten.

Testing it · 95

See all 95 studies that test sacituzumab tirumotecan →

Given in every arm · 13 — sacituzumab tirumotecan is usual care beside what is tested

Codes

What other systems call sacituzumab tirumotecan · ClinicalTrials.gg INT014653

UNII (FDA) 3DV5TD1VL3SACITUZUMAB TIRUMOTECANOne source FDA
NCI Thesaurus C166409Sacituzumab TirumotecanOne source FDA

System	Code	Name there	Checked by
UNII (FDA)	3DV5TD1VL3	SACITUZUMAB TIRUMOTECAN	One source FDA
NCI Thesaurus	C166409	Sacituzumab Tirumotecan	One source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.